J Korean Med Sci.  2016 Jun;31(6):924-931. 10.3346/jkms.2016.31.6.924.

Serum Chemerin Levels Are Associated with Abdominal Visceral Fat in Type 2 Diabetes

• Han J
• Kim SH
• Suh YJ
• Lim HA
• Shin H
• Cho SG
• Kim CW
• Lee SY
• Lee DH
• Hong S
• Kim YS
• Nam MS

• KMID: 2373702
• DOI: http://doi.org/10.3346/jkms.2016.31.6.924

Abstract

Chemerin is a recently identified adipokine suggested to play a role in obesity and its metabolic complications. The relationship between visceral obesity and serum chemerin levels in type 2 diabetes (T2DM) is unknown and may differ from that of subjects without diabetes. Therefore, we evaluated whether serum chemerin was associated with visceral abdominal obesity in patients with T2DM. A total of 218 Korean patients with T2DM were enrolled and metabolic parameters, abdominal visceral and subcutaneous fat areas, and serum chemerin levels were measured. Serum chemerin level showed positive correlation with fasting insulin, HOMA-IR, serum triglyceride, serum creatinine, urine albumin/creatinine ratio, high-sensitivity C-reactive protein (hsCRP), fibrinogen, abdominal visceral fat area, visceral to subcutaneous fat area ratio, and negatively correlation with high density lipoprotein cholesterol and creatinine clearance (CCr) after adjusting for age, gender and body mass index. Multiple linear stepwise regression analysis showed that abdominal visceral fat area (β = 0.001, P < 0.001), serum triglyceride (β = 0.001, P < 0.001), CCr (β = -0.003, P = 0.001), hsCRP (β = 0.157, P = 0.001), fibrinogen (β = 0.001, P < 0.001) and BMI (β = 0.02, P = 0.008) independently affected log transformed serum chemerin levels. Higher serum chemerin level was associated with higher level of abdominal visceral fat area, serum triglyceride, hsCRP and fibrinogen and lower level of CCr in patients with T2DM. Serum chemerin may be used as a biomarker of visceral adiposity and chemerin may play a role in inflammation, decreased renal function, and increased cardiovascular risk in T2DM.

Keyword

Chemerin; Abdominal Visceral Fat; Type 2 Diabetes Mellitus

MeSH Terms

Adult
Biomarkers/blood
Body Mass Index
C-Reactive Protein/analysis
Chemokines/*blood
Creatinine/blood/urine
Diabetes Mellitus, Type 2/*blood/diagnosis
Female
Humans
Insulin/blood
Intercellular Signaling Peptides and Proteins/*blood
Intra-Abdominal Fat/*pathology
Linear Models
Lipocalins/blood
Male
Middle Aged
Obesity/complications
Triglycerides/blood
Biomarkers
C-Reactive Protein
Chemokines
Creatinine
Insulin
Intercellular Signaling Peptides and Proteins
Lipocalins
Triglycerides

Figure

• 

  Fig. 1 Relationship between fat areas and serum chemerin levels after adjusting age, sex and BMI. (A) Abdominal visceral fat. (B) Abdominal subcutaneous fat.

Reference

1. Gallagher D, Kelley DE, Yim JE, Spence N, Albu J, Boxt L, Pi-Sunyer FX, Heshka S; MRI Ancillary Study Group of the Look AHEAD Research Group. Adipose tissue distribution is different in type 2 diabetes. Am J Clin Nutr. 2009; 89:807–814.

2. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, DeFronzo RA, Ferrannini E. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab. 2002; 87:5098–5103.

3. Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K, Islam AH, Keno Y, Kobatake T, Nagai Y, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis. 1994; 107:239–246.

4. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34:2–11.

5. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282:28175–28188.

6. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007; 148:4687–4694.

7. Kim SH, Lee SH, Ahn KY, Lee DH, Suh YJ, Cho SG, Choi YJ, Lee DH, Lee SY, Hong SB, et al. Effect of lifestyle modification on serum chemerin concentration and its association with insulin sensitivity in overweight and obese adults with type 2 diabetes. Clin Endocrinol (Oxf). 2014; 80:825–833.

8. Shin HY, Lee DC, Chu SH, Jeon JY, Lee MK, Im JA, Lee JW. Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin Endocrinol (Oxf). 2012; 77:47–50.

9. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26:3160–3167.

10. Hong SB, Lee JJ, Kim SH, Suh YJ, Han JY, Kim YS, Nam M. The effects of adiponectin and inflammatory cytokines on diabetic vascular complications in obese and non-obese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. Forthcoming. 2016.

11. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2006; 2:367–373.

12. Pouliot MC, Després JP, Nadeau A, Moorjani S, Prud’Homme D, Lupien PJ, Tremblay A, Bouchard C. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 1992; 41:826–834.

13. Kang SJ, Kim D, Park HE, Choi SH, Choi SY, Lee W, Kim JS, Cho SH. Visceral adipose tissue area is associated with coronary stenosis and noncalcified plaques. Int J Obes. 2014; 38:272–278.

14. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National Institutes of Health. Obes Res. 1998; 6:Suppl 2. 51S–209S.

15. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006; 580:2917–2921.

16. Müssig K, Staiger H, Machicao F, Thamer C, Machann J, Schick F, Claussen CD, Stefan N, Fritsche A, Häring HU. RARRES2, encoding the novel adipokine chemerin, is a genetic determinant of disproportionate regional body fat distribution: a comparative magnetic resonance imaging study. Metabolism. 2009; 58:519–524.

17. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009; 5:150–159.

18. Osman MM, El-mageed AI, El-hadidi E, Shahin RS, Mageed NA. Clinical utility of serum chemerin as a novel marker of metabolic syndrome and type 2 diabetes mellitus. Life Sci J. 2012; 9:1098–1108.

19. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, Mahaney MC, Rainwater DL, VandeBerg JL, MacCluer JW, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009; 94:3085–3088.

20. Dong B, Ji W, Zhang Y. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med. 2011; 50:1093–1097.

21. Takahashi M, Inomata S, Okimura Y, Iguchi G, Fukuoka H, Miyake K, Koga D, Akamatsu S, Kasuga M, Takahashi Y. Decreased serum chemerin levels in male Japanese patients with type 2 diabetes: sex dimorphism. Endocr J. 2013; 60:37–44.

22. Hu W, Feng P. Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Res Clin Pract. 2011; 91:159–163.

23. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004; 109:II2–10.

24. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420:868–874.

25. Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol. 2010; 185:3728–3739.

26. Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. Endocrinology. 2010; 151:2590–2602.

27. Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010; 21:660–667.

28. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schäffler A, Aslanidis C, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010; 72:342–348.

29. Yan Q, Zhang Y, Hong J, Gu W, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G. The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine. 2012; 41:281–288.

30. Barasch E, Benderly M, Graff E, Behar S, Reicher-Reiss H, Caspi A, Pelled B, Reisin L, Roguin N, Goldbourt U. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. J Clin Epidemiol. 1995; 48:757–765.

31. Bembde AS. A study of plasma fibrinogen level in type-2 diabetes mellitus and its relation to glycemic control. Indian J Hematol Blood Transfus. 2012; 28:105–108.

32. Pfau D, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care. 2010; 33:171–173.

33. Parlee SD, McNeil JO, Muruganandan S, Sinal CJ, Goralski KB. Elastase and tryptase govern TNFalpha-mediated production of active chemerin by adipocytes. PLoS One. 2012; 7:e51072.

34. Du XY, Leung LL. Proteolytic regulatory mechanism of chemerin bioactivity. Acta Biochim Biophys Sin (Shanghai). 2009; 41:973–979.